Exploring Predictive Factors for Bulevirtide Treatment Response in Hepatitis Delta-Positive Patients

<b>Background:</b> Hepatitis delta virus (HDV) infection represents the most severe form of viral hepatitis and is a significant global health challenge. Bulevirtide (BLV) is a novel therapeutic treatment that has resulted in variable response rates in HBV/HDV-coinfected patients. We eva...

Full description

Bibliographic Details

Published in:	Biomedicines
Main Authors:	Verdiana Zulian, Leonidas Salichos, Chiara Taibi, Silvia Pauciullo, Levi Dong, Gianpiero D’Offizi, Elisa Biliotti, Alessia Rianda, Luigi Federici, Angela Bibbò, Martina De Sanctis, Fiona McPhee, Anna Rosa Garbuglia
Format:	Article
Language:	English
Published:	MDPI AG 2025-01-01
Subjects:	HDV bulevirtide antiviral treatment Anti-HBc IgG genetic variability
Online Access:	https://www.mdpi.com/2227-9059/13/2/280